Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: Notoriety Bias or True Ocular Toxicity?
- Design
- Mendelian randomization
- Drugs
- Semaglutide
- Assessment
- Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Oct 18, 2026
This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved. This item has not been peer reviewed.
01Source
The source, as retrieved
Abstract
ObjectiveTo determine whether the semaglutide-NAION association reflects true toxicity or reporting bias. Research design and methodsWe performed temporal disproportionality analysis of FDA Adverse Event Reporting System (FAERS) data (2018Q1-2026Q2) to detect reporting anomalies and class-level spillover, and GLP1R cis-eQTL drug-target Mendelian randomization (MR) of NAION-relevant ocular phenotypes to test causal effects of GLP1R activation on semaglutide-relevant ocular toxicity. ResultsSemaglutide ROR was 116.8 (95% CI 106.8-127.7). FAERS rates rose from below 8 per 10,000 annually (2018-2023) to 52 (2024), 177 (2025), and 203 (2026H1) after July 2024 publication, while comparators remained stable. Median time to onset was 246 days (Weibull {beta} = 1.09), a random-type profile inconsistent with cumulative toxicity. These anomalies were complemented by GLP1R-targeted MR evidence: no causal effect of genetically proxied GLP1R activation (all P [≥] 0.11), while confirming glucose-lowering (P = 7.6E-6). ConclusionsPharmacovigilance and genetic evidence converge to show that the semaglutide-NAION signal reflects notoriety bias rather than toxicity.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| medrxiv:medrxiv | Sep 20, 2026 | 10.64898/2026.09.06.26362369 first ingestion |
| medrxiv:medrxiv | Nov 1, 2026 | 10.64898/2026.09.06.26362369 duplicate matched on doi |
| owner-review | Nov 6, 2026 | reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision. |